Pubblicazioni

PUBBLICAZIONI
1. GAVIOLI R, GALLERANI E., FORTINI C, FABRIS M, BOTTONI A, CANELLA A, BONACCORSI A, MARASTONI M., MICHELETTI F, CAFARO A, RIMESSI P, CAPUTO A, ENSOLI B (2004). HIV-1 Tat protein modulates the generation of cytotoxic T cell epitopes by modifying proteasome composition and enzymatic activity. JOURNAL OF IMMUNOLOGY, vol. 173; p. 3838-3843,
2. REMOLI A.L, MARSILI G, PERROTTI E, GALLERANI E., ILARI R, NAPPI F, CAFARO A, ENSOLI B, GAVIOLI R., BATTISTINI A. (2006). Intracellular HIV-1 tat protein represses constitutive LMP2 transcription increasing proteasome activity by interfering with the binding of IRF-1 to STAT1. BIOCHEMICAL JOURNAL, vol. 396; p. 371-380,
3. GAVIOLI R, CELLINI S, CASTALDELLO A, VOLTAN R, GALLERANI E., GAGLIARDONI F, FORTINI C, COFANO EB, TRIULZI C, CAFARO A, SRIVASTAVA I, BARNETT S, CAPUTO A, ENSOLI B. (2008). The Tat protein broadens T cell responses directed to the HIV-1 antigens Gag and Env: Implications for the design of new vaccination strategies against AIDS. VACCINE vol. 26; p. 727-737
4. S. CELLINI, C. FORTINI, GALLERANI E., F. DESTRO, E. B. COFANO, A. CAPUTO, R. GAVIOLI (2008). Identification of new HIV-1 Gag-specific cytotoxic T lymphocyte responses in BALB/c mice. VIROLOGY JOURNAL, vol. 5; p. 81-87. doi: 10.1186/1743-422X-5-81.
5. DESTRO F, SFORZA F, SICURELLA M, MARESCOTTI D, GALLERANI E, BALDISSEROTTO A, MARASTONI M, GAVIOLI R. (2011). Proteasome inhibitors induce the presentation of an EBNA1-derived CTL epitope in Burkitt’s lymphoma cells. IMMUNOLOGY, 133; p.105-114. doi: 10.1111/j.1365-2567.2011.03416.x.
6. NICOLI F, FINESSI V, SICURELLA M, RIZZOTTO L, GALLERANI E, DESTRO F, CAFARO A, MARCONI P, CAPUTO A, Ensoli B, Gavioli R. (2013) The HIV-1 Tat protein induces the activation of CD8+ T cells and affects in vivo the magnitude and kinetics of antiviral responses. PLoS One. 8; e77746. doi: 10.1371/journal.pone.0077746.
7. SICURELLA M, NICOLI F, GALLERANI E, VOLPI I, BERTO E, FINESSI V, DESTRO F, MANSERVIGI R, CAFARO A, ENSOLI B, CAPUTO A, GAVIOLI R, MARCONI PC. (2014) An attenuated herpes simplex virus type 1 (HSV1) encoding the HIV-1 Tat protein protects mice from a deadly mucosal HSV1 challenge. PLoS One. 9; e100844. doi: 10.1371/journal.pone.0100844.
8. SFORZA F, NICOLI F, GALLERANI E, FINESSI V, REALI E, CAFARO A, CAPUTO A, ENSOLI B, GAVIOLI R. (2014) HIV-1 Tat affects the programming and functionality of human CD8⁺ T cells by modulating the expression of T-box transcription factors. AIDS. 28;1729-1738. doi: 10.1097/QAD.0000000000000315.
9. FINESSI V, NICOLI F, GALLERANI E, SFORZA F, SICURELLA M, CAFARO A, CAPUTO A, ENSOLI B, GAVIOLI R. (2015) Effects of different routes of administration on the immunogenicity of the Tat protein and a Tat-derived peptide. HUM VACCIN IMMUNOTHER. 11; p.1489-93. doi: 10.1080/21645515.2015.1016676.
10. FINOTTI A, GASPARELLO J, BREVEGLIERI G, COSENZA LC, MONTAGNER G, BRESCIANI A, ALTAMURA S, BIANCHI N, MARTINI E, GALLERANI E, BORGATTI M, GAMBARI R. (2015) Development and characterization of K562 cell clones expressing BCL11A-XL: Decreased hemoglobin production with fetal hemoglobin inducers and its rescue with mithramycin. EXP HEMATOL. 43; p.1062-1071. doi: 10.1016/j.exphem.2015.08.011.
11. AVITABILE C, ACCARDO A, RINGHIERI P, MORELLI G, SAVIANO M, MONTAGNER G, FABBRI E, GALLERANI E, GAMBARI R, ROMANELLI A. (2015). Incorporation of Naked Peptide Nucleic Acids into Liposomes Leads to Fast and Efficient Delivery. Bioconjug Chem. 26:1533-41. doi: 10.1021/acs.bioconjchem.5b00156.
12. SCOTTI A, TRAPELLA C, FERRETTI V, GALLERANI E, GAVIOLI R, MARASTONI M. (2016) Studies of C-terminal naphthoquinone dipeptides as 20S proteasome inhibitors. J ENZYME INHIB MED CHEM. 31;p.456-463. doi: 10.3109/14756366.2015.1037749.
13. NICOLI F, GALLERANI E, SKARLIS C, SICURELLA M, CAFARO A, ENSOLI B, CAPUTO A, MARCONI PC, GAVIOLI R. (2016) Systemic immunodominant CD8 responses with an effector-like phenotype are induced by intravaginal immunization with attenuated HSV vectors expressing HIV Tat and mediate protection against HSV infection. VACCINE. 34; p.2216-24. doi: 10.1016/j.vaccine.2016.03.022.
14. NAVACCHIA ML, FRAIX A, CHINAGLIA N, GALLERANI E, PERRONE D, CARDILE V, GRAZIANO AC, CAPOBIANCO ML, SORTINO S. (2016) NO Photoreleaser-Deoxyadenosine and -Bile Acid Derivative Bioconjugates as Novel Potential Photochemotherapeutics. ACS MED CHEM LETT. 7; p.939-943.
15. ZAMARIOLA G, WATLY J, GALLERANI E, GAVIOLI R, GUERRINI R, KOZLOWSKI H, REMELLI M. (2016) AGHLDDLPGALSAL: A hemoglobin fragment potentially competing with albumin to bind transition metal ions. J INORG BIOCHEM. 163; p.301-310. doi: 10.1016/j.jinorgbio.2016.04.001.
16. SGUIZZATO M, CORTESI R, GALLERANI E, DRECHSLER M, MARVELLI L, MARIANI P, CARDUCCI F, GAVIOLI R, ESPOSITO E, BERGAMINI P. (2017) Solid lipid nanoparticles for the delivery of 1,3,5-triaza-7-phosphaadamantane (PTA) platinum (II) carboxylates. MATER SCI ENG C MATER BIOL APPL., 74; p.357-364 doi: 10.1016/j.msec.2016.12.020.
17. NAVACCHIA ML, MARCHESI E, MARI L, CHINAGLIA N, GALLERANI E, GAVIOLI R, CAPOBIANCO ML, PERRONE D. (2017) Rational Design of Nucleoside-Bile Acid Conjugates Incorporating a Triazole Moiety for Anticancer Evaluation and SAR Exploration. MOLECULES. 22 pii: E1710.
18. NICOLI F, GALLERANI E, SFORZA F, FINESSI V, CHACHAGE M, GELDMACHER C, CAFARO A, ENSOLI B, CAPUTO A, GAVIOLI R. (2018) The HIV-1 Tat protein affects human CD4+ T-cell programing and activation, and favors the differentiation of naïve CD4+ T cells. AIDS. 32; p.575-581. doi: 10.1097/QAD.0000000000001734.
19. PACIFICO S, FERRETTI V, ALBANESE V, FANTINATI A, GALLERANI E, NICOLI F, GAVIOLI R, ZAMBERLAN F, PRETI D, MARASTONI M. (2019) Synthesis and Biological Activity of Peptide α-Ketoamide Derivatives as Proteasome Inhibitors. ACS Med Chem Lett. 10:1086-1092. doi: 10.1021/acsmedchemlett.9b00233.
20. NICOLI F, GALLERANI E, SICURELLA M, PACIFICO S, CAFARO A, ENSOLI B, MARCONI P, CAPUTO A, GAVIOLI R. (2020) The Tat Protein of HIV-1 Prevents the Loss of HSV-Specific Memory Adaptive Responses and Favors the Control of Viral Reactivation. Vaccines (Basel). 8:274. doi: 10.3390/vaccines8020274.
21. NICOLI F, MANTELLI B, GALLERANI E, TELATIN V, BONAZZI I, MARCONI P, GAVIOLI R, GABRIELLI L, LAZZAROTTO T, BARZON L, PALÙ G, CAPUTO A. (2020) HPV-Specific Systemic Antibody Responses and Memory B Cells are Independently Maintained up to 6 Years and in a Vaccine-Specific Manner Following Immunization with Cervarix and Gardasil in Adolescent and Young Adult Women in Vaccination Programs in Italy. Vaccines (Basel). 2020 8:26. doi: 10.3390/vaccines8010026.
22. GALLERANI E, PROIETTO D, DALLAN B, CAMPAGNARO M, PACIFICO S, ALBANESE V, MARZOLA E, MARCONI P, CAPUTO A, APPAY V, GAVIOLI R, NICOLI F. (2021). Impaired Priming of SARS-CoV-2-Specific Naive CD8+ T Cells in Older Subjects. Front Immunol. 2021 12:693054. doi: 10.3389/fimmu.2021.693054.
23. NICOLI F, PACIFICO S, GALLERANI E, MARZOLA E, ALBANESE V, FINESSI V, LLEWELLYN-LACEY S, PRICE DA, APPAY V, MARCONI P, GUERRINI R, CAPUTO A, GAVIOLI R. (2021). Use of a Novel Peptide Welding Technology Platform for the Development of B- and T-Cell Epitope-Based Vaccines. Vaccines (Basel). 2021 9:526. doi: 10.3390/vaccines9050526.
24. NICOLI F, CABRAL-PICCIN MP, PAPAGNO L, GALLERANI E, FUSARO M, FOLCHER V, DUBOIS M, CLAVE E, VALLET H, FRERE JJ, GOSTICK E, LLEWELLYN-LACEY S, PRICE DA, TOUBERT A, DUPRÉ L, BODDAERT J, CAPUTO A, GAVIOLI R, APPAY V (2022). Altered Basal Lipid Metabolism Underlies the Functional Impairment of Naive CD8+ T Cells in Elderly Humans. J Immunol. 208:562-570. doi: 10.4049/jimmunol.2100194.
25. NICOLI F, MANTELLI B, GALLERANI E, TELATIN V, SQUARZON L, MASIERO S, GAVIOLI R, PALÙ G, BARZON L, CAPUTO A. (2022). Effects of the age of vaccination on the humoral responses to a human papillomavirus vaccine. NPJ Vaccines. 7:37. doi: 10.1038/s41541-022-00458-0.
26. BARBARI R, TUPINI C, DURINI E, GALLERANI E, NICOLI F, LAMPRONTI I, BALDISSEROTTO A, MANFREDINI S. (2022). Design, Synthesis and Evaluation of New Multifunctional Benzothiazoles as Photoprotective, Antioxidant and Antiproliferative Agents. Molecules. 28:287. doi: 10.3390/molecules28010287.